Pneumagen's primary focus lies in the development of glycan-targeted carbohydrate binding modules (CBMs) as an innovative universal therapeutic approach for addressing respiratory tract infections (RTIs) and cancer. Established in 2016, the organization emerged as a spin-out from the University of St Andrews in Scotland, benefiting from access to top-tier scientific proficiency and capabilities in glycobiology.